Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design.

[1]  C. O'connor,et al.  The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. , 2004, Journal of cardiac failure.

[2]  Daniel Levy,et al.  Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.

[3]  M. Redfield,et al.  Heart failure--an epidemic of uncertain proportions. , 2002, The New England journal of medicine.

[4]  R Brian Haynes,et al.  Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial , 1999, The Lancet.

[5]  U. Goldbourt,et al.  Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. , 1999, Journal of the American College of Cardiology.

[6]  B. Gersh,et al.  Racial differences in the outcome of left ventricular dysfunction. , 1999, The New England journal of medicine.

[7]  M. Ezekowitz.  Antithrombotics for left-ventricular impairment? , 1998, The Lancet.

[8]  W. Rand,et al.  Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. , 1998, Journal of the American College of Cardiology.

[9]  W. Rand,et al.  Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. , 1998, Journal of the American College of Cardiology.

[10]  T. Meade,et al.  Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk , 1998, The Lancet.

[11]  W. O'Fallon,et al.  Survival and recurrence after first cerebral infarction , 1998, Neurology.

[12]  A. Algra,et al.  Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke , 1997, Journal of the Neurological Sciences.

[13]  M. Rich,et al.  CONGESTIVE HEART FAILURE IN OLDER ADULTS * : Epidemiology, Pathophysiology, and Etiology of Congestive Heart Failure in Older Adults , 1997, Journal of the American Geriatrics Society.

[14]  B. Massie,et al.  Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. , 1997, American heart journal.

[15]  J. Cleland.  Anticoagulant and antiplatelet therapy in heart failure. , 1997, Current opinion in cardiology.

[16]  M. Domanski,et al.  Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. , 1997, Journal of the American College of Cardiology.

[17]  G. Lamas,et al.  Ventricular dysfunction and the risk of stroke after myocardial infarction. , 1997, The New England journal of medicine.

[18]  M. Hennerici,et al.  The Feasibility of a Collaborative Double-Blind Study Using an Anticoagulant , 1997 .

[19]  M. Dennis.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[20]  H. Diener,et al.  European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke 1 1 ESPS-2 Writing Committee , 1996, Journal of the Neurological Sciences.

[21]  L. Tavazzi,et al.  Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients. , 1996, European heart journal.

[22]  D. Singer,et al.  An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. , 1996, The New England journal of medicine.

[23]  L. S. Mortensen,et al.  Prognostic value of echocardiography in 190 patients with chronic congestive heart failure. A comparison with New York Heart Association functional classes and radionuclide ventriculography. , 1996, Cardiology.

[24]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[25]  P. Koudstaal.  Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. , 1995, The New England journal of medicine.

[26]  J. Halperin,et al.  Atrial fibrillation and stroke. Revisiting the dilemmas. , 1994, Stroke.

[27]  R. Sacco,et al.  Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community , 1994, Neurology.

[28]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[29]  T. LeJemtel,et al.  Low incidence of stroke in ambulatory patients with heart failure: a prospective study. , 1993, American heart journal.

[30]  J. Cohn,et al.  Incidence of Thromboembolic Events in Congestive Heart Failure , 1993, Circulation.

[31]  C Warlow,et al.  The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[32]  M. Laakso,et al.  The European Stroke Prevention Study , 1991, Neurology.

[33]  P Smith,et al.  The effect of warfarin on mortality and reinfarction after myocardial infarction. , 1990, The New England journal of medicine.

[34]  R. Falk.  A plea for a clinical trial of anticoagulation in dilated cardiomyopathy. , 1990, The American journal of cardiology.

[35]  V. Fuster,et al.  Left ventricular thrombi and cerebral embolism. , 1989, The New England journal of medicine.

[36]  J. Cairns,et al.  Antithrombotic agents in coronary artery disease. , 1989, Chest.

[37]  J Whitehead,et al.  A FORTRAN program for the design and analysis of sequential clinical trials. , 1983, Computers and biomedical research, an international journal.

[38]  P. Wolf,et al.  Manifestations of coronary disease predisposing to stroke. The Framingham study. , 1983, JAMA.

[39]  F. J. Moore,et al.  A study of the beneficial effects of anticoagulant therapy in congestive heart failure. , 1952, Annals of internal medicine.

[40]  G. Anderson,et al.  The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. , 1950, American heart journal.

[41]  W. P. Harvey,et al.  Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. , 1950, The New England journal of medicine.

[42]  P. White,et al.  Acute pulmonary congestion and cardiac asthma in patients with mitral stenosis , 1934 .